These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

677 related items for PubMed ID: 15583670

  • 21. Patents: a threat to innovation?
    Manocaran M.
    Science; 2010 Jan 01; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract] [Full Text] [Related]

  • 22. A generic problem.
    Hanauer SB.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec 01; 3(12):649. PubMed ID: 17130869
    [No Abstract] [Full Text] [Related]

  • 23. Canada to change patent law to allow export of cheap drugs.
    Kondro W.
    Lancet; 2003 Oct 18; 362(9392):1290. PubMed ID: 14577437
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT.
    Mich Law Rev; 2015 Oct 18; 114(1):107-36. PubMed ID: 26394458
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC.
    Food Drug Law J; 2004 Oct 18; 59(1):155-68. PubMed ID: 15190929
    [No Abstract] [Full Text] [Related]

  • 32. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA.
    J Contemp Health Law Policy; 1992 Oct 18; 8():361-78. PubMed ID: 10118987
    [No Abstract] [Full Text] [Related]

  • 33. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003 Oct 18; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. US trade rules seek to balance health and patent protection.
    Wadman M, Cherry M.
    Nature; 1999 Dec 09; 402(6762):567-8. PubMed ID: 10604448
    [No Abstract] [Full Text] [Related]

  • 38. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.
    Kim J, Ross JS, Kapczynski A.
    JAMA; 2018 Jan 02; 319(1):21-22. PubMed ID: 29117365
    [No Abstract] [Full Text] [Related]

  • 39. Overview of the Hatch-Waxman Act and its impact on the drug development process.
    Mossinghoff GJ.
    Food Drug Law J; 1999 Jan 02; 54(2):187-94. PubMed ID: 11758572
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.